Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LifeCycle Pharma or LCP has launched its first product, the cholesterol lowering drug for the treatment of hyperlipidemia and hypertriglyceridemia, under the name Fenoglide in the US. Fenoglide will be marketed by its partner Sciele Pharma.
Subscribe to our email newsletter
Fenoglide will be the lowest dose of fenofibrate available for patients. Fenoglide will be offered in 40mg and 120mg strength tablets. Fenoglide utilizes LCP’s unique MeltDose technology, a clinically validated reformulation technology, designed to provide enhanced absorption and greater bioavailability of the drug.
Fenoglide will be marketed by Sciele Pharma’s more than 400 sales representatives across its diabetes and cardiovascular sales force teams.
According to the agreement with Sciele Pharma, LCP will receive tiered royalty payments on product sales and may also receive milestone payments of up to $8 million when certain sales targets are met.
Patrick Fourteau, CEO of Sciele Pharma, said: “We expect the launch of Fenoglide, the lowest dose fenofibrate available to patients, will enable us to increase our share of the fenofibrate market, which is one of the fastest growing areas of the cardiovascular market.”